Olesoxime

Olesoxime
Identifiers
	IUPAC name (NZ)-N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine;
CAS Number	22033-87-0;
PubChem CID	21763506;
ChemSpider	23350363;
UNII	A6778U5IFY;
KEGG	D11213;
CompTox Dashboard (EPA)	DTXSID001029582 ;
Chemical and physical data
Formula	C27H45NO
Molar mass	399.663 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C/C(=N\O)/CC[C@]34C)C;
	InChI InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/t19-,22+,23-,24+,25+,26+,27-/m1/s1; Key:QNTASHOAVRSLMD-GYKMGIIDSA-N;

Olesoxime (TRO19622) is an experimental drug formerly under development by the now-defunct French company Trophos as a treatment for a range of neuromuscular disorders. It has a cholesterol-like structure and belongs to the cholesterol-oxime family of mitochondrial pore modulators.

Identifiers

IUPAC name (NZ)-N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine
CAS Number	22033-87-0
PubChem CID	21763506
ChemSpider	23350363
UNII	A6778U5IFY
KEGG	D11213
CompTox Dashboard (EPA)	DTXSID001029582
Chemical and physical data
Formula	C₂₇H₄₅NO
Molar mass	399.663 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C/C(=N\O)/CC[C@]34C)C
InChI InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/t19-,22+,23-,24+,25+,26+,27-/m1/s1 Key:QNTASHOAVRSLMD-GYKMGIIDSA-N